UDCA and COVID-19

This dashboard explores the relationship between UDCA (ursodeoxycholic acid) and COVID-19 incidence/severity. It addresses the following question: Does UDCA decrease the risk of inpatient hospitalization among adults with COVID-19?

Select a Topic to Explore:

This work is supported by the National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Grant number 3R01HD105939-01S1 and the National Center for Advancing Translational Sciences, Grant Number U24TR002306. This work is solely the responsibility of the creators and does not necessarily represent the official views of the National Institutes of Health.